Stryker (NYSE:SYK) Issues Earnings Results, Beats Expectations By $0.14 EPS

Stryker (NYSE:SYK) posted its quarterly earnings data on Tuesday. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14, Zacks reports. Stryker had a return on equity of 23.07% and a net margin of 16.34%. During the same quarter in the previous year, the firm posted $3.46 earnings per share. Stryker updated its FY 2025 guidance to 13.450-13.700 EPS.

Stryker Trading Down 1.2 %

NYSE:SYK opened at $394.92 on Wednesday. Stryker has a 1 year low of $310.74 and a 1 year high of $406.19. The stock has a market cap of $150.55 billion, a price-to-earnings ratio of 42.33, a PEG ratio of 2.68 and a beta of 0.95. The business has a fifty day moving average of $376.32 and a 200-day moving average of $361.59. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a $0.84 dividend. This is a boost from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.85%. Stryker’s dividend payout ratio is presently 36.01%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on SYK shares. Needham & Company LLC reiterated a “buy” rating and set a $442.00 price objective on shares of Stryker in a research report on Tuesday, January 7th. Canaccord Genuity Group lifted their price target on Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $370.00 to $445.00 in a report on Monday, December 2nd. Royal Bank of Canada restated an “outperform” rating and issued a $425.00 price target on shares of Stryker in a report on Tuesday, January 7th. Finally, Wells Fargo & Company lifted their price target on Stryker from $405.00 to $427.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average target price of $405.80.

Insider Activity

In other news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 5.50% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.